Peptide questions · BPC-157

BPC-157 side effects: what studies and users report

Reviewed Evidence: EmergingPublished by PepVault

The side effects most commonly reported for BPC-157 are nausea (rare), injection site irritation and vivid dreams, among 4 the library lists; its evidence in people comes from small studies without a control group and from clinical use.

Its safety note opens: A 2025 peer-reviewed review (McGuire et al., Curr Rev Musculoskelet Med, Univ. of Utah) confirms human evidence is limited to three tiny uncontrolled studies by a single investigator — ~16 knee patients, ~12 interstitial-cystitis patients, and 2 IV subjects (up to 20 mg, no adverse events) — with no controls, and says the lack of high-quality human trials limits the ability to assess its safety in people.

What is commonly reported with BPC-157

  • Nausea (rare)
  • Injection site irritation
  • Vivid dreams
  • Dizziness

Common here means the library lists it among the effects people most often report; the list doesn’t say how often each one happens.

Each effect, and the other healing & recovery compounds the library lists it for
EffectAlso listed for (of 18)
Nausea (rare)6: TB-500, AOD-9604, Larazotide, ARA-290 and 2 more
Injection site irritation1: KPV
Vivid dreamsNone: listed for BPC-157 alone
Dizziness2: Teriparatide, Abaloparatide
A smiling man in a grey t-shirt in his living room, holding his phone

PepVault for iPhone

Track BPC-157 in PepVault

Log each dose and any side effect beside it, so you can see what changed and when.

Download on the App Store

7 days free on the yearly plan for new subscribers.

Which BPC-157 side effects the healing & recovery group shares

Across the 19 healing & recovery compounds in the library, the effects listed most often are headache (7 of 19), injection site reaction (7 of 19), nausea (rare) (7 of 19) and fatigue (6 of 19). BPC-157 shares 3 of its 4 listed effects with at least one other healing & recovery compound; vivid dreams is listed for BPC-157 alone.

What the BPC-157 safety notes say

The library’s safety note

A 2025 peer-reviewed review (McGuire et al., Curr Rev Musculoskelet Med, Univ. of Utah) confirms human evidence is limited to three tiny uncontrolled studies by a single investigator — ~16 knee patients, ~12 interstitial-cystitis patients, and 2 IV subjects (up to 20 mg, no adverse events) — with no controls, and says the lack of high-quality human trials limits the ability to assess its safety in people. Most safety data otherwise comes from rodent and dog studies, where it was well tolerated with no serious toxicity and a very short plasma half-life (~15 min in rats). Community use reports mostly transient injection-site reactions. Note the regulatory status: WADA-banned since 2022 (S0). FDA's compounding list (April 2026) shows BPC-157 as previously in category 2, substances that may pose significant safety risks, and since withdrawn by its nominators; FDA still flags a possible risk of immune reactions to compounded versions and says it has little or no safety information. A theoretical caution worth raising: its proangiogenic activity could in principle support unwanted tissue (e.g. tumor) growth — not observed in the small human data, but uncharacterized. Discuss with your clinician; this is not an approved drug and long-term human safety is unestablished.

The library’s interaction note

No published human drug-interaction studies exist for BPC-157 with any medication class (SSRIs, anticoagulants, insulin/antidiabetics, thyroid meds). Animal work has explored interactions with the serotonergic and nitric-oxide systems, but this does not translate to clinical dosing guidance. Its proangiogenic activity is a theoretical consideration in people with a personal/family history of cancer. Discuss any prescription medications with your clinician.

These are reference notes from published research and reported use, not advice for a person: discuss your own situation with your clinician.

Where the BPC-157 reports come from

The library rates the evidence on BPC-157 as emerging: mostly preclinical, with limited human data.

Of the library’s 9 research notes on BPC-157, 6 rest on animal studies and 3 on community reports.

Our 14 study pages on BPC-157: 10 animal studies (rats), 1 clinical trial, 1 animal study (mice), 1 observational study and 1 cell study (rat Achilles tendon fibroblasts).

So the effects listed for BPC-157 come from uncontrolled studies and use in people, not from placebo-controlled trials.

What our BPC-157 study pages report on safety

BPC-157: 10 of 12 women reported full interstitial cystitis relief

Clinical trial, human, 2024: No one left the study, and no side effects were reported.

BPC-157 closed duodenocolic fistulas in rats

Animal study, rats, 2024: In rats, every BPC-157-treated animal closed both the duodenal and the colonic defect, with no fistula leakage, no diarrhea and no wasting, and kept its pre-surgery weight. Control rats kept both defects open and had ongoing leakage, diarrhea, steady weight loss, heavy adhesions and intestinal obstruction.

Questions people ask

What are the side effects of BPC-157?

The side effects most commonly reported for BPC-157 are nausea (rare), injection site irritation and vivid dreams, among 4 the library lists; its evidence in people comes from small studies without a control group and from clinical use.

Do BPC-157’s side effects come from human studies?

The library rates the evidence on BPC-157 as emerging, and its evidence in people comes from small studies without a control group and from clinical use.

Which BPC-157 side effects are its own?

Among the healing & recovery compounds, the library lists vivid dreams for BPC-157 alone.

Does BPC-157 interact with other medicines?

The library’s interaction note on BPC-157 begins: No published human drug-interaction studies exist for BPC-157 with any medication class (SSRIs, anticoagulants, insulin/antidiabetics, thyroid meds).

More on BPC-157

Track it in the app

PepVault for iPhone

Track BPC-157 in PepVault

Log each dose and any side effect beside it, so you can see what changed and when.

Download on the App Store

7 days free on the yearly plan for new subscribers.

Explore the live demo